Mink therapeutics to report first quarter 2023 corporate update and financial results

New york, april 27, 2023 (globe newswire) -- mink therapeutics, inc. (nasdaq: inkt), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer t (inkt) cell therapies to treat cancer and other immune-mediated diseases, today announced that the company will release its first quarter 2023 financial results before the market opens on thursday, may 11, 2023. members of the mink leadership team will host a conference call and webcast at 8:30 a.m. et that morning to discuss the results and to provide a corporate update.
INKT Ratings Summary
INKT Quant Ranking